Ann: Appendix 4C Quarterly Activity Report, page-60

"Concurrently, Mesoblast will also explore potential strategic initiatives with a number of global pharma companies who have existing interests in cardiovascular disease and/or major vascular complications of diabetes."

Well weekend is here in Oz so wondering if fellow posters have heard of the following in pharma world?

Should there be multiple suitors chasing a Deal in the CHF space, the biggest worldwide medical market worth billions of recurring revenue year after year, might management consider selling rite to make last offer?

So US$50 to US$100 million, nothing to a big pharma, to have last say?

I humbly suggest management might find a willing buyer for that rite.

Now snorters I know what your going to write however that's no need to be rude!!

I promise giving snorters a sleepless weekend was furtherest thing from my mind!!